Michael Wang

List of Publications by Year
in descending order

68 papers	1,232 citations	471509 17 h-index	395702 33 g-index
70 all docs	70 docs citations	70 times ranked	1320 citing authors

#	Article	IF	Citations
1	A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood, 2019, 134, 2127-2138.	1.4	241
2	Low-Dose Tissue Plasminogen Activator Thrombolysis in Children. Journal of Pediatric Hematology/Oncology, 2003, 25, 379-386.	0.6	143
3	Risk factors for in-hospital venous thromboembolism in children: a case-control study employing diagnostic validation. Haematologica, 2012, 97, 509-515.	3.5	101
4	Selfâ€reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (Pâ€FiQ) study. Haemophilia, 2017, 23, 556-565.	2.1	90
5	Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patientâ€reported outcome instruments in the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 5-13.	2.2	37
6	<scp>2021</scp> clinical trials update: Innovations in hemophilia therapy. American Journal of Hematology, 2021, 96, 128-144.	4.1	37
7	Impact of pain and functional impairment in <scp>US</scp> adults with haemophilia: Patientâ€reported outcomes and musculoskeletal evaluation in the pain, functional impairment and quality of life (Pâ€FiQ) study. Haemophilia, 2018, 24, 261-270.	2.1	36
8	Cardiac findings and long-term thromboembolic outcomes following pulmonary embolism in children: a combined retrospective-prospective inception cohort study. Cardiology in the Young, 2013, 23, 344-352.	0.8	32
9	Internal consistency and item-total correlation of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adult people with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1831-1839.	1.8	27
10	Arginine vasopressin ameliorates spatial learning impairments in chronic cerebral hypoperfusion via V1a receptor and autophagy signaling partially. Translational Psychiatry, 2017, 7, e1174-e1174.	4.8	25
11	PERSEPT 1: a phase 3 trial of activated eptacog beta for onâ€demand treatment of haemophilia inhibitorâ€related bleeding. Haemophilia, 2017, 23, 832-843.	2.1	23
12	Metaâ€analysis of natural, unnatural and causeâ€specific mortality rates following discharge from inâ€patient psychiatric facilities. Acta Psychiatrica Scandinavica, 2019, 140, 244-264.	4.5	23
13	Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). Haemophilia, 2021, 27, 87-95.	2.1	23
14	Malawi Polyomavirus Is a Prevalent Human Virus That Interacts with Known Tumor Suppressors. Journal of Virology, 2015, 89, 857-862.	3.4	21
15	Metaâ€analysis of suicide rates among people discharged from nonâ€psychiatric settings after presentation with suicidal thoughts or behaviours. Acta Psychiatrica Scandinavica, 2019, 139, 472-483.	4.5	21
16	Prognostic significance of immune cells in the tumor microenvironment and peripheral blood of gallbladder carcinoma patients. Clinical and Translational Oncology, 2017, 19, 477-488.	2.4	18
17	An amino acid change near the carboxyl terminus of the Streptococcus gordonii regulatory protein Rgg affects its abilities to bind DNA and influence expression of the glucosyltransferase gene gtfG. Microbiology (United Kingdom), 2003, 149, 399-406.	1.8	17
18	Known-group validity of patient-reported outcome instruments and hemophilia joint health score v2.1 in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1745-1753.	1.8	17

#	Article	IF	Citations
19	Safety and doseâ€dependency of eptacog beta (activated) in a dose escalation study of nonâ€bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia, 2017, 23, 844-851.	2.1	15
20	Reliability of patient-reported outcome instruments in US adults with hemophilia: the Pain, Functional Impairment and Quality of life (P-FiQ) study. Patient Preference and Adherence, 2017, Volume 11, 1603-1612.	1.8	15
21	Humanism and professionalism education for pediatric hematologyâ€oncology fellows: A model for pediatric subspecialty training. Pediatric Blood and Cancer, 2015, 62, 335-340.	1.5	14
22	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of Thrombosis and Haemostasis, 2022, 20, 857-865.	3.8	14
23	Intestinal Tight Junction in Allograft After Small Bowel Transplantation. Transplantation Proceedings, 2007, 39, 289-291.	0.6	13
24	Manganese superoxide dismutase induction during measles virus infection. Journal of Medical Virology, 2003, 70, 470-474.	5.0	12
25	Realâ€world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5Âyears. Haemophilia, 2020, 26, 975-983.	2.1	12
26	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood, 2022, 140, 89-98.	1.4	12
27	The Hemophilia Gene Therapy Patient Journey: Questions and Answers for Shared Decision-Making. Patient Preference and Adherence, 0, Volume 16, 1439-1447.	1.8	12
28	Venous thromboembolism in children with cystic fibrosis: Retrospective incidence and intrapopulation risk factors. Thrombosis Research, 2017, 158, 161-166.	1.7	11
29	Impact of haemophilia on patients with mildâ€toâ€moderate disease: Results from the Pâ€FiQ and Bâ€HEROâ€S studies. Haemophilia, 2021, 27, 8-16.	2.1	11
30	First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies. Blood, 2020, 136, LBA-6-LBA-6.	1.4	11
31	Patientâ€reported outcomes and joint status across subgroups of <scp>US</scp> adults with hemophilia with varying characteristics: Results from the Pain, Functional Impairment, and Quality of Life (Pâ€FiQ) study. European Journal of Haematology, 2018, 100, 14-24.	2.2	10
32	Multicentric Castleman Disease Presenting with Fever. Journal of Pediatrics, 2014, 165, 1261-1265.	1.8	9
33	Association of TLR2 and TLR4 non-missense single nucleotide polymorphisms with type 2 diabetes risk in a southern Chinese population: a case-control study. Genetics and Molecular Research, 2015, 14, 8694-8705.	0.2	9
34	Association between miR-137 polymorphism and risk of schizophrenia: a meta-analysis. Genetics and Molecular Research, 2016, 15, .	0.2	8
35	Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A singleâ€center report. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12571.	2.3	8
36	Identification of patients with congenital hemophilia in a large electronic health record database. Journal of Blood Medicine, 2017, Volume 8, 131-139.	1.7	7

#	Article	IF	Citations
37	Identification of people with acquired hemophilia in a large electronic health record database. Journal of Blood Medicine, 2017, Volume 8, 89-97.	1.7	7
38	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
39	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq1 1 0.784314 rgBT /Ove	2.1	7
40	Treatment of refractory hemorrhage with factor XIII in a patient with hemophilia A with inhibitor. Pediatric Blood and Cancer, 2013, 60, E23-5.	1.5	6
41	Measuring pediatric hematologyâ€“oncology fellowsâ€™ skills in humanism and professionalism: A novel assessment instrument. Pediatric Blood and Cancer, 2017, 64, e26316.	1.5	6
42	Optimal trough levels in haemophilia B: Raising expectations. Haemophilia, 2020, 26, e334-e336.	2.1	6
43	Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTIONâ€TOâ€HOPE): Results of a survey of US haemophilia treatment centre professionals. Haemophilia, 2020, 26, 20-30.	2.1	6
44	Realâ€world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: A followâ€up retrospective analysis. Haemophilia, 2021, 27, 19-25.	2.1	6
45	Association between IL2/IL21 and SH2B3 polymorphisms and risk of celiac disease: a meta-analysis. Genetics and Molecular Research, 2015, 14, 13221-13235.	0.2	6
46	Breakthrough Bleeding in Hemophilia a Patients on Prophylaxis. Blood, 2016, 128, 2581-2581.	1.4	5
47	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq1 1 0.784314 rgBT /Overl 2021, 27, 911-920.	2.1	5
48	Acute Influence of FK506 on T-Lymphocyte Populations of Peripheral Blood and Spleen in Rats. Transplantation Proceedings, 2007, 39, 292-294.	0.6	4
49	von Willebrand disease Outreach into Integrated Care Education (VOICE): a call to action. Haemophilia, 2017, 23, e370-e373.	2.1	3
50	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1035-1045.	2.3	3
51	Transition of care for pediatric and adult patients with venous thromboembolism: A National Quality Improvement Project from the American Thrombosis and Hemostasis Network (ATHN). Thrombosis Research, 2021, 200, 23-29.	1.7	3
52	Safety and effectiveness of a risk-stratified venous thromboembolism prophylaxis algorithm in young people with cystic fibrosis. Thrombosis Research, 2021, 206, 36-41.	1.7	3
53	THE PSYCHOLOGICAL CONSEQUENCES OF AWARENESS DURING SURGERY. , 2000, , .		3
54	Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient-Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood, 2015, 126, 39-39.	1.4	3

#	Article	IF	Citations
55	Single 225Î¼g/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Î' or Î' with Inhibitors: A PERSEPT1 Subset Analysis. Blood, 2020, 136, 2-3.	1.4	2
56	Identification of Persons with Acquired Hemophilia in a Large Electronic Health Record Database. Blood, 2015, 126, 3271-3271.	1.4	2
57	Linear and Logistic Regression Models of Patient-Reported Outcomes and Patient Characteristics in US Adults with Hemophilia from the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study. Blood, 2016, 128, 252-252.	1.4	2
58	Thinned-out skin paddle versus collagen matrix as an optimized peri-implant soft tissue following fibula osteoseptocutaneous free flap: 3-year retrospective study. International Journal of Oral and Maxillofacial Surgery, 2021, 50, 391-397.	1.5	1
59	The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Blood, 2017, 130, 756-756.	1.4	1
60	Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. Pediatric Blood and Cancer, 2021, 68, e28577.	1.5	0
61	Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center. Acta Haematologica, 2021, 144, 672-677.	1.4	0
62	Feasibility of Delivering Pediatric-to-Adult Transition Education during Annual Comprehensive Clinic Appointments and Patient-Reported Outcomes: A Quality Improvement Study. Blood, 2021, 138, 2993-2993.	1.4	0
63	Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. Blood, 2021, 138, 1039-1039.	1.4	0
64	Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial. Blood, 2021, 138, 3972-3972.	1.4	0
65	Inhibit Clinical Trials Platform to Prevent and Eradicate Inhibitors: Feasibility Survey of Current Prophylaxis and Immune Tolerance Practices. Blood, 2020, 136, 14-15.	1.4	0
66	Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia a and B. Blood, 2020, 136, 2-3.	1.4	0
67	Retrospective Chart Review of Gastrointestinal Bleeding in Patients with Von Willebrand Disease. Blood, 2020, 136, 20-21.	1.4	0
68	Left bundle branch pacing preserves ventricular mechanical synchrony better than right ventricular pacing-a two-center study. Europace, 2022, 24, .	1.7	0